Results

Total Results: 1,134 records

Showing results for "days".

241. Slide 1 (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/marketing_evidence_evans.ppt
     September 13, 2006 - Slide 1 Marketing “evidence” to healthcare consumers: Applying social marketing to evidence about the harms and benefits of pharmaceuticals Presented by W. Douglas Evans, Ph.D. Lauren McCormack, Ph.D., M.S.P.H Presented at Agency for Healthcare Research and Quality Conference: Communicating Harms and Benefits of …

242. Research Protocol: Safety of Vaccines Used for Routine Immunization in the United States (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/safety-vaccines-protocol.pdf
     January 30, 2020 - (https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html) are safe in the short term (within 42 days … following immunization) or long term (>42 days after immunization)? … following immunization) or long term (>42 days after immunization)? … vaccines recommended for pregnant women in the United States are safe in the short term (within 42 days … following immunization) or long term (>42 days after immunization) for both the woman and her fetus

243. Migraine-Prevention Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-prevention_executive.pdf
     June 01, 2013 - frequency is classified as either episodic or chronic2 according to the number of monthly migraine days … , with episodic being <15 days, and chronic Effective Health Care Program The Effective Health Care … being ≥15 days. … Topiramate increased the likelihood of ≥75 percent reduction in migraine days more often than placebo … , 52 to 311) per 1,000 treated would experience a reduction of at least 75 percent in migraine days

244. Evidence Summary: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-221-copd-evidence-summary_0.pdf
     October 01, 2019 - The mean treatment duration was 9.9 days and there was a mean 3.7 months of reported followup. … lowered payments to Inpatient Prospective Payment System hospitals with too many readmissions within 30 days

245. App-F2-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
     May 29, 2025 - TCA_PCT Table F-2a. Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time (Wk) Time Category WAE: n WAE: N SAE: n SAE: N Cardiac Rhythm Abnormalities: Specific AE Cardiac Rhythm Abnormalities: n Cardiac Rhythm Abnormalities: N N Randomized Cognitive Eff…

246. Improving Medication Safety in High Risk Medicare Beneficiaries Toolkit (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medication-therapy-management-1_research.pdf
     July 01, 2012 - outcomes were the number of ADEs, hospital admissions, and emergency room (ER) visits at 90 and 180 days … Our program featured two visits with the medication therapy management provider spaced 90 days apart … in medication, new prescriber visit, ER visit, hospitalization, invasive procedure within last 30 days … Followup Visit A followup MTM visit was conducted 90 to 120 days after the first MTM visit. … Generic (trade) Dosage Form and # (Ex: qday, bid, tid, qid, qod) (Ex: DM,HTN, ≤ 30 days

247. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - , 3–14 cm), mean procedure time was 145 minutes (43–240 minutes), and mean length of stay was 2.2 days … (1–5 days). … No complications occurred requiring intensive care, hospital stays longer than 5 days, surgical or … Additionally, after 12 months of teduglutide treatment, 53% of patients reduced their infusion days … per week and 24% of patients reduced their infusion days per week by 3 or more days.

248. Treatment of Dementia Among Community-Dwelling and Institutionalized Medicare Beneficiaries (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dementia-databases-methods_research.pdf
     May 01, 2008 - out of bed or chairs, walking, and using the toilet), presence of depression, mortality, inpatient days … (hospitals, LTC facility, Medicare qualified SNF days), and, for nursing home residents only, severity … Depression 594,641 29.7 (1.88) 658,575 47.1 (2.45) Mortality 322,295 16.1 (1.47) 324,732 23.2 (1.71) Days … Facility 6.3 (1.14) 288.7 (4.54) Medicare qualified SNF stay 5.0 (0.62) 14.8 (1.62) Community-days … 328.3 (3.23) 25.6 (2.67) Total days 339.5 (2.75) 329.1 (3.49) aData from those with available

249. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-atrial-fibrillation_research-protocol.pdf
     January 30, 2012 - Warfarin-naïve patients experience a three-fold increased risk of bleeding in the first 90 days of treatment … atrial flutter):  Including paroxysmal AF (recurrent episodes that self-terminate in less than 7 days … ), persistent AF (recurrent episodes that last more than 7 days), and permanent AF (an ongoing long-term … including atrial flutter): o Paroxysmal AF (recurrent episodes that self- terminate in less than 7 days … ) o Persistent AF (recurrent episodes that last more than 7 days) o Permanent AF (an ongoing, long-term

250. Pneumonia-Antibiotic-Treatment Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pneumonia-antibiotic-treatment_executive.pdf
     November 01, 2014 - meets one or more of several criteria: had been hospitalized in an acute care hospital for 2 or more days … within 90 days of the infection; had resided in a nursing home or long-term care facility; had received … recent intravenous (IV) antibiotic therapy, chemotherapy, or wound care within the 30 days preceding … might include the types of intermediate outcomes we sought—such as immediate clinical response or days … important data on other outcomes of interest to both clinicians and patients; these include ventilator days

251. Treatment of Stage I-III Squamous Cell Anal Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/anal-cancer-protocol.pdf
     September 26, 2023 - fluorouracil (5- FU), in which the dose is calculated from the patient’s body surface area and is given on days … 1-4 and, again, on days 29-32, and Mitomycin-C (MMC), administered as a bolus on days 1 and 29.8 These … Treatment breaks (frequency or duration), treatment discontinuation, interruptions, or median treatment days

252. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/vaccine-safety_research-protocol.pdf
     September 18, 2012 - 2011 immunization schedule recommended for U.S. adults18* are safe in the short term (within 30–42 days … following immunization) or long term (>42 days after immunization)? … recommended for U.S. children and adolescents in 201119* are safe in the short term (within 30–42 days … following immunization) or long term (>42 days after immunization)?

253. Minimal Modeling Approaches to Value of Information Analysis for Health Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-future-value-of-information_research.pdf
     June 01, 2011 - The primary outcome was resolution of symptoms within 5 days.41 At day 5, 70/236 patients (29.7%) in … Mean time to symptom resolution within 14 days of treatment initiation for each treatment was obtained … (SE=0.260) compared to 8.12 days (SE=0.210) for patients receiving amoxicillin/clavulanate (p value … as $125 billion—suggests that when a minimal modeling approach to VOI can be applied, the several days … horizon 10 years 5 year Discounting 3% 3% (Cost-)effectiveness results - Effectiveness = -0.57 days

254. new disposition of comments insulin analogues -- jda revs.xls (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/insulin-analogues-disposition-081229.pdf
     September 01, 2008 - new disposition of comments insulin analogues -- jda revs.xls                                                                                                                                                Comment, by Section Response Executive Summary Comment: A statement under Gaps in Evidence and Future Direction…

255. VTE Surveillance Assessment_49_low_SPI (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/blood-clots-hip-knee-surgery_surveillance.pdf
     December 01, 2012 - or longer compared with thromboprophylaxis for 7 to 10 days on symptomatic objectively confirmed venous … Third, are the baseline rates you cite for the period of 7-10 days or up to 28 days? … or longer compared with thromboprophylaxis for 7 to 10 days on symptomatic objectively confirmed VTE … for 7 to 10 days in patients who had major orthopedic surgery. … for 7 to 10 days in patients who had major orthopedic surgery.

256. Making Healthcare Safer IV Rapid Response_Active Surveillance Culturing of Clostridioides difficile and Multidrug-Resistant Organisms: Methicillin-Resistant Staphylococcus aureus, Carbapenem-Resistant Enterobacterales, and Candida auris (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mhs4-active-infection-rapid-response.pdf
     May 01, 2024 - overall MRSA infections, MRSA bloodstream infections, or rate of MRSA infections per 1,000 patient days … to 2.9 cases/10,000 patient days. … active surveillance: 2.9 cases per 10,000 days; p<0.001) Calaway, 201920 Pre-post Assess the … risk factors: age >65 years old; transferred from other health institutions; hospital stay >7 days … ; treatment with carbapenem, 3rd- or 4th- generation cephalosporin, or fluoroquinolone for >3 days

257. Microsoft Word - finapps.doc (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-artery-stenosis_appendixes-2007.pdf
     January 01, 2007 - stenting, patients received ticlopidine 250 mg twice daily or clopidogrel 75 mg/day for more than 30 days … stenting, patients received ticlopidine 250 mg twice daily or clopidogrel 75 mg/day for more than 30 days … G Patients who died within 180 days excluded from analyses of annual changes SCr. … atherosclerotic renal artery stenosis; CKD, chronic kidney disease; CVD, cardiovascular disease; d, days

258. Topic Brief: Interventions to Decrease Hospital Length of Stay (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-hospital-length-of-stay.pdf
     November 01, 2019 - Issue: Unnecessary days in the hospital can lead to patient complications and increases costs. … newborns/neonates, septicemia, osteoarthritis, and congestive heart failure.1 2 • Unnecessary days … article describes a complex discharge subcommittee that focuses on patients with LOS more than 10 days … Extra bed-days could account for up to 30.7% of total costs and cause cancellations of elective operations … The mean delay was 3.15 days (median 2 days) with a range of 1-42 days.

259. PATIENTSLIKEME (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/clifford.pdf
     May 29, 2025 - natural language processing on what makes it -- what makes a person with multiple sclerosis's very bad days … different from what makes their -- what makes their very -- their very good days very good.

260. Disclosure Policy and Form (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/epc-disclosure-policy-form.pdf
     March 01, 2023 - duration of their participation in the report, they must update and resubmit a disclosure form within 7 days … - I agree to update and resubmit this form within 7 days of entering into any new financial … duration of their participation in the report, they must update and resubmit a disclosure form within 7 days … duration of their participation in the report, they must update and resubmit a disclosure form within 7 days …           -  I agree to update and resubmit this form within 7 days of entering into any new financial